Co-administration of Carcinoembryonic Antigen and Hiv Tat Fusion Protein with Cpg-oligodeoxynucleotide Induces Potent Antitumor Immunity Although Dendritic Cells (dc) Have Been Well Demonstrated as a Strong Cellular Adjuvant for a Tumor Vaccine, There Are Several Limitations for Clinical Application
Asia,Chang-Hyun Kim,Mi-Young Park,Hye‐Sung Kim,Sun-Je Woo,Hyung‐Jin Kim,Jung‐Sun Park,Tai-Gyu Kim,H. Sohn,Blackwell Publishing,Seong-Taek Oh
Abstract:O ligodeoxynucleotides (ODN) containing unmethylated CpG motifs can activate B cells, dendritic cells (DC), and natural killer (NK) cells, as well as induce a Th1 cell-like pattern of cytokine production. (1–4) Moreover, CpG-ODN enhances humoral responses, driving them toward immunoglobulin (Ig)G2a, IgG2b, and IgG3 isotypes (Th1 type indicator), (5) and enhances cytotoxic T-lymphocytes (CTL) activity. (6) Co-administering CpG-ODN with protein antigens, subunit vaccines, or DNA vaccines is both safe and effective in enhancing immunity in an animal challenge model. (7–9) CpG-ODN are internalized to endosomes, leading to acidification and recognition by the TLR9 trigger and nuclear factor (NF)-κB activation. The HIV-1 TAT peptide can transport macromolecules into cells and allows proteins to be used as immunogens for major histocompatibility complex (MHC) class I-restricted CTL responses. (12) TAT peptides from derived PTD protein are transported rapidly from the extracellular milieu into the cytosol. These cationic peptides can efficiently deliver 20-to 200-kDa proteins, peptides, liposomes, or antisense oligonucleotides into cells. (10) Therefore, the adjuvant effect of ODN could enhance immune responses by binding them to TAT peptides fused with antigen proteins. Carcinoembryonic antigen (CEA) is a 180-kDa oncofetal glycoprotein and soluble tumor marker. It is extensively expressed in the vast majority of colorectal, gastric, and pancreatic carcinomas, in approximately 50% of breast cancers, and in 70% of non-small cell lung cancers. (14) Several vaccine approaches, including peptides, viral vectors and dendritic cells, have been performed for human and experimental studies for the treatment of tumors expressing CEA. (15–17) The authors have previously reported that DC transduced with recombinant adenoviruses expressing CEA, or DC pulsed with peptide of CEA, have been demonstrated to stimulate strong tumor-antigen-specific CTL responses in vitro, (18) and to induce antitumor immunity in vivo in animal models, (19) respectively. Thus, the DC-based vaccine approach is well established for human and experimental studies. However, DC are sparse in peripheral blood mononuclear cells (PBMC) and do not proliferate readily in vitro, despite the report of Romani et al. (20) Therefore heavy leukapheresis is sometimes required for DC preparation in cancer patients, who quite often have damaged bone marrow (the source of the cells) because of treatments with radiation and/or antitumor drugs. Protein-based vaccines such as TAT-fusion protein have become an appealing approach to inducing antigen-specific immuno-therapy because of their simplicity, safety, efficacy and capacity for repeated administration. In the present study, the authors demonstrated that the combination of TAT-CEA fusion protein …
Medicine